Not Signed In - Ranbaxy Receives USFDA Approval To Market 80mg Simvastatin Tablets With 180-Day Exclusivity
Mon, 26 Jun 2006 07:00 AM EST
... Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Simvastatin Tablets USP, 80mg with 180-day exclusivity in the U.S. [click link for full article] ...
Related Topics
- Day Care
- Child Day Care
- Research
- Simvastatin
- Carbinoxamine and Pseudoephedrine Tablets
- Cerivastatin - Withdrawn From The Market
- Vaccine Testing & Approval
- Carbinoxamine and Pseudoephedrine Extended-Release Tablets
- Five a Day Fruits and Vegetables
- Cyanocobalamin Tablets
- Tragacanth
- Chlorpheniramine, Pseudoephedrine and Hydrocodone Tablets
- Guaifenesin and Dextromethorphan
- Neostigmine Tablets
- Haloperidol Tablets
- Thiabendazole Tablets
- Rofecoxib Oral Suspension
- Carbetapentane, Phenylephrine, and Pyrilamine
- Home Care
- Procaine
email this page
print this page
bookmark this page
feedback on this page
